Google’s new AI will help researchers understand how our genes work

When scientists first sequenced the human genome in 2003, they revealed the full set of DNA instructions that make a person. But we still didn’t know what all those 3 billion genetic letters actually do. Now Google’s DeepMind division says it’s made a leap in trying to understand the code with AlphaGenome, an AI model that predicts what effects small changes in DNA will have on an array of molecular processes, such as whether a gene’s activity will go up or down. In this edition of What’s Next in Tech, learn more about how AlphaGenome will help us understand how our genes work.

⚡ What's Next in Tech Readers: Claim your special, FREE 30-day trial subscription today.

First came AlphaFold. Now comes AlphaGenome for DNA.

Five years ago, Google DeepMind released AlphaFold, a technology for predicting the 3D shape of proteins. That work was honored with a Nobel Prize last year and spawned a drug-discovery spinout, Isomorphic Labs, and a boom of companies that hope AI will be able to propose new drugs.

AlphaGenome is an attempt to further smooth biologists’ work by answering basic questions about how changing DNA letters alters gene activity and, eventually, how genetic mutations affect our health. 

“We have these 3 billion letters of DNA that make up a human genome, but every person is slightly different, and we don’t fully understand what those differences do,” says Caleb Lareau, a computational biologist at Memorial Sloan Kettering Cancer Center who has had early access to AlphaGenome. “This is the most powerful tool to date to model that.”

Google says AlphaGenome will be free for noncommercial users and plans to release full details of the model in the future. According to Kohli, the company is exploring ways to “enable use of this model by commercial entities” such as biotech companies. 

Lareau says AlphaGenome will allow certain types of experiments now done in the lab to be carried out virtually, on a computer. For instance, studies of people who’ve donated their DNA for research often turn up thousands of genetic differences, each slightly raising or lowering the chance a person gets a disease such as Alzheimer’s.

Lareau says DeepMind’s software could be used to quickly make predictions about how each of those variants works at a molecular level, something that would otherwise require time-consuming lab experiments. “You’ll get this list of gene variants, but then I want to understand which of those are actually doing something, and where can I intervene,” he says. “This system pushes us closer to a good first guess about what any variant will be doing when we observe it in a human.” Read the story.

Get the most important health, medical science, and biotech news in your inbox with our in-depth weekly newsletter, The Checkup. Sign up for free today.

Get ahead with these related stories:

1. We’re learning more about what weight-loss drugs do to the body — GLP-1 agonists like Wegovy, Ozempic, and Mounjaro might benefit heart and brain health—but research suggests they might also cause pregnancy complications and harm some users.
2. This baby boy was treated with the first personalized gene-editing drug — The one-off treatment highlights the promise of a new type of gene editing and the challenges of using it to treat extremely rare genetic diseases.
3. Adventures in the genetic time machine — Ancient DNA is telling us more and more about humans and environments long past. Could it also help rescue the future?

Image: Science Photo Library